PROVECTUS BIOPHARMACEUTICALS, INC. — fact timeline

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Authorization to amend Certificate of Incorporation to decrease authorized shares of common and preferred stock by the reverse stock split ratio at the 2026-06-18 meeting.

“Proposal 5 . The Company’s stockholders authorized the Board, given the Company’s stockholders’ approval of Proposal 4, to amend the Company’s Certificate of Incorporation, as amended by the Certificates of Designation, to decrease the number of authorized shares of the Company’s common stock and preferred stock by the same reverse stock split ratio determined by the Board, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 311,771,119 Against 22,227,876 Abstention 5,831,898”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Authorization to amend Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-10 and 1-for-50 at the 2026-06-18 meeting.

“Proposal 4 . The Company’s stockholders authorized the Board to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50, where the ratio would be determined by the Board at its discretion, and to make corresponding amendments to the Certificates of Designation to provide for the proportional adjustment of certain terms upon a reverse stock split, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 315,344,309 Against 23,622,833 Abstention 863,751”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Ratification of selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for 2026 at the 2026-06-18 meeting.

“Proposal 3 . The Company’s stockholders ratified the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for 2026, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 329,742,597 Against 7,6914,122 Abstention 2,474,174”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-18 meeting.

“Proposal 2 . The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive officers, consistent with the Board’s recommendation. There were 131,619,889 broker non-votes with respect to the proposal. Number of Votes For 190,162,705 Against 16,667,960 Abstention 1,380,339”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1 . The Company’s stockholders elected the following directors for a term of one-year, consistent with the recommendation of the Company’s board of directors (the “Board”). There were 131,619,889 broker non-votes with respect to the proposal. Name of Candidate Number of Votes For Withhold Authority Webster Bailey 191,823,174 16,387,830 John Lacey, III, M.D. 191,947,635 16,263,369 Ed Pershing, CPA 197,553,672 10,657,332 Dominic Rodrigues 192,036,957 16,174,047”

PROVECTUS BIOPHARMACEUTICALS, INC.: Extended the automatic conversion date of Series D and Series D-1 Convertible Preferred Stock from June 20, 2026 to December 31, 2028 (effective 2026-01-30).

“On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.”

PROVECTUS BIOPHARMACEUTICALS, INC. engaged CBIZ CPAs P.C. as its auditor.

“ovember 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum LLP (“Marcum”), and substantially”

Marcum LLP resigned as auditor of PROVECTUS BIOPHARMACEUTICALS, INC..

“Marcum resigned as the independent registered public accounting firm of the Company”

Dominic Rodrigues was appointed as President at PROVECTUS BIOPHARMACEUTICALS, INC..

“appointed Dominic Rodrigues as the Company’s President effective April 16, 2024.”

Ed Pershing was appointed as Chief Executive Officer at PROVECTUS BIOPHARMACEUTICALS, INC..

“appointed Ed Pershing as the Company’s Chief Executive Officer effective April 16, 2024.”

PROVECTUS BIOPHARMACEUTICALS, INC. entered into Exclusive License Agreement with University of Miami (effective 2024-03-21).

“On March 21, 2024, Provectus Biopharmaceuticals, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with the University of Miami (the “University”) for the license and development of the University’s intellectual property related to photodynamic antimicrobial therapy in ophthalmology.”

Dominic Rodrigues was appointed as Chief Operations Consultant at PROVECTUS BIOPHARMACEUTICALS, INC..

“the Board retained Dominic Rodrigues as the Company’s chief operations consultant.”

Bruce Horowitz resigned as Director at PROVECTUS BIOPHARMACEUTICALS, INC..

“On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.”

Bruce Horowitz resigned as Chief Operating Officer at PROVECTUS BIOPHARMACEUTICALS, INC..

“On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Authorize the Board to amend the Certificate of Incorporation to decrease the number of authorized shares of common stock and preferred stock by the same reverse stock split ratio determined by the Board, contingent on approval of Proposal 5. at the 2023-06-21 meeting.

“Proposal 6 . The Company’s stockholders authorized the Board, given the Company’s stockholders’ approval of Proposal 5, to amend the Company’s Certificate of Incorporation, as amended by the Certificates of Designation, to decrease the number of authorized shares of the Company’s common stock and preferred stock by the same reverse stock split ratio determined by the Board, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 325,415,362 Against 17,597,706 Abstention 13,715,779”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Authorize the Board to amend the Certificate of Incorporation to effect a reverse stock split of common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio between 1-for-10 and 1-for-50, with ratio determined by the Board. at the 2023-06-21 meeting.

“Proposal 5 . The Company’s stockholders authorized the Board to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50, where the ratio would be determined by the Board at its discretion, and to make corresponding amendments to the Certificates of Designation to provide for the proportional adjustment of certain terms upon a reverse stock split, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 321,704,418 Against 28,885,597 Abstention 6,138,832”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Ratification of Marcum LLP as independent registered public accounting firm for 2023. at the 2023-06-21 meeting.

“Proposal 4 . The Company’s stockholders ratified the selection of Marcum LLP as the Company’s independent registered public accounting firm for 2023, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 354,414,074 Against 1,760,851 Abstention 553,922”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Advisory vote on the frequency of the advisory vote on executive compensation. at the 2023-06-21 meeting.

“Proposal 3 . The Company’s stockholders approved a one-year frequency of the advisory vote on the compensation of the Company’s named executive officers. There were no broker non-votes with respect to the proposal. In light of the voting results on Proposal 3, the Company’s Board of Directors has determined that an advisory vote to approve the compensation of the Company’s named executive officers will be conducted every year, until the Company holds the next required stockholder advisory vote on the frequency of obtaining an advisory vote on named executive officer compensation. Number of Votes 1 Year 225,357,358 2 Years 4,889,414 3 Years 3,921,828 Abstain 5,756,165”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Advisory vote on the compensation of the Company’s named executive officers. at the 2023-06-21 meeting.

“Proposal 2 . The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive officers, consistent with the Board’s recommendation. There were 116,804,082 broker non-votes with respect to the proposal. Number of Votes For 226,093,665 Against 9,461,763 Abstention 4,369,337”

PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Election of directors for a one-year term. at the 2023-06-21 meeting.

“Proposal 1 . The Company’s stockholders elected the following directors for a term of one-year, consistent with the recommendation of the Company’s board of directors (the “Board”). There were 116,804,082 broker non-votes with respect to the proposal. Name of Candidate Number of Votes For Withhold Authority Webster Bailey 236,246,350 3,678,415 Bruce Horowitz 227,745,308 12,179,457 John Lacey, III, M.D. 229,468,606 10,456,259 Ed Pershing, CPA 236,214,269 3,710,496 Dominic Rodrigues 227,932,827 11,991,938”